title: Osteopontin (OPN) improves risk stratification in pulmonary hypertension (PH).
authors.forename: Mark
authors.initials: M
authors.lastname: Rosenberg
authors.forename: F Joachim
authors.initials: FJ
authors.lastname: Meyer
authors.forename: Ekkehard
authors.initials: E
authors.lastname: Gruenig
authors.forename: Tibor
authors.initials: T
authors.lastname: Schuster
authors.forename: Matthias
authors.initials: M
authors.lastname: Lutz
authors.forename: Dirk
authors.initials: D
authors.lastname: Lossnitzer
authors.forename: Rita
authors.initials: R
authors.lastname: Wipplinger
authors.forename: Hugo A
authors.initials: HA
authors.lastname: Katus
authors.forename: Norbert
authors.initials: N
authors.lastname: Frey
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002423:Cause of Death / Q000639:trends; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood* / Q000401:mortality / Q000503:physiopathology; D008297:Male; D053495:Osteopontin / Q000096:biosynthesis*; D011446:Prospective Studies; D011669:Pulmonary Wedge Pressure; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends; D015854:Up-Regulation / Q000502:physiology*; D014655:Vascular Resistance
chemical_list: D015415:Biomarkers; D053495:Osteopontin